Global health status and fatigue score in IDH-mutant diffuse glioma grades 2 and 3 – A longitudinal population-based study from surgery to 12-month follow-up

IF 2.4 Q2 CLINICAL NEUROLOGY

Neuro-oncology practice Pub Date : 2024-03-01 DOI:10.1093/nop/npae017

T. Gómez Vecchio, I. Rydén, A. Ozanne, M. Blomstrand, L. Carstam, A. Smits, A. Jakola

{"title":"Global health status and fatigue score in IDH-mutant diffuse glioma grades 2 and 3 – A longitudinal population-based study from surgery to 12-month follow-up","authors":"T. Gómez Vecchio, I. Rydén, A. Ozanne, M. Blomstrand, L. Carstam, A. Smits, A. Jakola","doi":"10.1093/nop/npae017","DOIUrl":null,"url":null,"abstract":"\n \n \n At group level, health-related quality of life (HRQoL) in patients with IDH-mutant diffuse glioma grade 2 and 3 seems to remain stable over time. However, clinical experience indicates that there are patients with unfavorable outcomes on key HRQoL subdomains. The aim of this longitudinal population-based study, following patients over a period of 12 months from surgery, was to describe individual level data on global health status and fatigue score and explore possible predictors of deterioration.\n \n \n \n All patients undergoing surgery for presumed glioma grade 2 or 3 at the Sahlgrenska University Hospital during 2017-2022, were screened for the study. Patients were invited to complete the EORTC core questionnaires and brain module at baseline, 3 and 12 months postoperatively. Data is reported with respect to minimal clinical important difference (MCID).\n \n \n \n We included 51 patients with IDH-mutant diffuse glioma grade 2 or 3. There was no difference in group level data of either global health status or fatigue score from baseline to the 12-month follow-up (p-value >0.05). Unfavorable individual changes (beyond MCID) in global health status and fatigue score were observed in 12 and in 17 patients respectively (23.5% and 33.3%). A lower proportion of proton radiotherapy was found in patients with unfavorable changes in fatigue (10/15, 66.7%) compared to all other patients undergoing radiotherapy (22/23, 95.7%, p-value 0.03).\n \n \n \n Deterioration beyond MCID was seen in approximately one-third of patients. Changes in global health status could not be predicted, but changes in fatigue may be influenced by tumor-targeted and symptomatic treatment.\n","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/nop/npae017","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

At group level, health-related quality of life (HRQoL) in patients with IDH-mutant diffuse glioma grade 2 and 3 seems to remain stable over time. However, clinical experience indicates that there are patients with unfavorable outcomes on key HRQoL subdomains. The aim of this longitudinal population-based study, following patients over a period of 12 months from surgery, was to describe individual level data on global health status and fatigue score and explore possible predictors of deterioration. All patients undergoing surgery for presumed glioma grade 2 or 3 at the Sahlgrenska University Hospital during 2017-2022, were screened for the study. Patients were invited to complete the EORTC core questionnaires and brain module at baseline, 3 and 12 months postoperatively. Data is reported with respect to minimal clinical important difference (MCID). We included 51 patients with IDH-mutant diffuse glioma grade 2 or 3. There was no difference in group level data of either global health status or fatigue score from baseline to the 12-month follow-up (p-value >0.05). Unfavorable individual changes (beyond MCID) in global health status and fatigue score were observed in 12 and in 17 patients respectively (23.5% and 33.3%). A lower proportion of proton radiotherapy was found in patients with unfavorable changes in fatigue (10/15, 66.7%) compared to all other patients undergoing radiotherapy (22/23, 95.7%, p-value 0.03). Deterioration beyond MCID was seen in approximately one-third of patients. Changes in global health status could not be predicted, but changes in fatigue may be influenced by tumor-targeted and symptomatic treatment.

查看原文本刊更多论文

IDH突变弥漫性胶质瘤2级和3级患者的总体健康状况和疲劳评分--一项从手术到12个月随访的纵向人群研究

在群体层面上，IDH突变弥漫性胶质瘤2级和3级患者的健康相关生活质量（HRQoL）似乎随着时间的推移而保持稳定。然而，临床经验表明，有些患者在关键的 HRQoL 子域上结果不佳。这项以人群为基础的纵向研究对手术后12个月内的患者进行跟踪，目的是描述总体健康状况和疲劳评分的个体水平数据，并探索可能的恶化预测因素。这项研究筛选了2017-2022年期间在瑞典萨赫格伦斯卡大学医院接受推测为2级或3级胶质瘤手术的所有患者。患者受邀在基线、术后 3 个月和 12 个月完成 EORTC 核心问卷和脑模块。数据以最小临床重要差异（MCID）进行报告。我们共纳入了 51 名 2 级或 3 级 IDH 突变弥漫性胶质瘤患者。从基线到 12 个月随访期间，总体健康状况或疲劳评分的组间数据均无差异（P 值 >0.05）。分别有 12 名和 17 名患者（23.5% 和 33.3%）的总体健康状况和疲劳评分出现了不利的个体变化（超出 MCID）。与所有其他接受放疗的患者（22/23，95.7%，P 值 0.03）相比，疲劳出现不利变化的患者接受质子放疗的比例较低（10/15，66.7%）。约三分之一的患者病情恶化程度超过了 MCID。总体健康状况的变化无法预测，但疲劳的变化可能会受到肿瘤靶向治疗和对症治疗的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neuro-oncology practice CLINICAL NEUROLOGY-

CiteScore

5.30

自引率

11.10%

发文量

期刊介绍： Neuro-Oncology Practice focuses on the clinical aspects of the subspecialty for practicing clinicians and healthcare specialists from a variety of disciplines including physicians, nurses, physical/occupational therapists, neuropsychologists, and palliative care specialists, who have focused their careers on clinical patient care and who want to apply the latest treatment advances to their practice. These include: Applying new trial results to improve standards of patient care Translating scientific advances such as tumor molecular profiling and advanced imaging into clinical treatment decision making and personalized brain tumor therapies Raising awareness of basic, translational and clinical research in areas of symptom management, survivorship, neurocognitive function, end of life issues and caregiving